Background: Current chemotherapy for acute myeloid leukemia (AML) mainly involves cytotoxic agents such as doxorubicin (DNR), mitoxantrone (Mito) or 2-aminopurine-6-thiol (6-TG). However, because these agents are relatively ineffective, discovering other more effective drugs for AML treatment would be valuable.
| INTRODUC TI ON
Acute myeloid leukemia (AML) is hematological malignancy that has been characterized by infiltration of the bone marrow, blood and other hematopoietic tissues. 1, 2 Current chemotherapeutic options for AML include cytotoxic agents such as DNR, Mito, etoposide and 6-TG. 3, 4 However, treatment of AML patients with these agents has not shown the expected promising outcomes. Due to the complex multiple causes of AML, it is hard to achieve tumor regression by simply administrating a single functional cytotoxic agent. 5 Over the last decade, molecule-targeting agents have become widely recognized as "first choice" treatments for certain hardcore tumors, and researchers have now started to focus on treating one kind of tumor using kinase inhibitors approved to treat another. 6, 7 A number of studies have provided insights into the genetic variability of AML and indicated potential targets for drug development.
In addition to mutations found in genes including NPM1, CEBPA, DNMT3A, TET2, RUNX1, ASXL1, IDH2, and MLL, dysfunctional receptor tyrosine kinases (RTKs) such as Flt, VEGFR or c-Kit have been shown to be drivers of the progress of AML. 5, 8 Therefore, it would be valuable to discover whether effective existing kinase inhibitors restrict AML tumors.
Lenvatinib is a newly approved multi-targeted kinase inhibitor. 9 Oral administration of lenvatinib can repress the proliferation or metastasis 2 | MATERIAL S AND ME THODS MHCC97 To examine cell proliferation inhibition, 2000 cells were seeded into 96-well culture plates. The cells were then treated with different concentrations of lenvatinib (1, 0.3, 0.1, 0.03, 0.01, 0.003 or 0.00 μmol/L) for 48 hours. Next cell metabolic activity was measured by MTT assay.
| Cell lines and agents

| Cell culture and proliferation inhibition testing
Briefly, MTT assays were performed using the following methods. MTT reagent (50 mg/mL) was added to the wells of a 96-well culture plate and after about 4 hours the plates were centrifuged to attach the cells to the bottom of the plates. The supernatant was discarded and about 200 μL DMSO was added to each well. After standing for about 10 minutes, the plates were shaken to break up the cells. The plates were then centrifuged to remove the resulting foam and screened using a platereader to obtain the absorbance of samples at a wavelength of 490 nm. 
| Subcutaneous growth of AML cells
The animal experiments were approved by the Institutional Animal Care and Use Committee of The Fifth Medical Center (former name:
The 302nd Hospital of Chinese PLA), General Hospital of Chinese People's Liberation Army (the ID of certification: IACUC-2019-001, Figure S1 ). All the animal studies were conducted in accordance with the UK Animals (Scientific Procedures) Act of 1986 and the asso- 
| Subcutaneous tumor tissue shape regularity
Photographs of subcutaneous tumors were quantitatively analyzed to determine the length of the long axis of the tumor, and the area of the perfect circle (the total number of pixels) having the diameter of the long axis was calculated. At the same time, the tumor tissue was delineated by marking the edge of the tumor on the photograph and the total area of the tumor tissue (total number of pixels) was calculated. The ratio of the total area of the long-axis circle to the total area of the delineated tumor reflected the regularity of the shape of the tumor tissue: the closer the ratio to 1, the more regular the shape of the tumor tissue.
| Statistical analysis
Statistical analysis was performed using a Bonferroni correction with two-way analysis of variance and P < 0.05 were considered as statistically significant between groups. The statistical analysis was performed using SPSS software (IBM Corporation) and the IC 50 values of lenvatinib on AML cells were calculated using Origin software (OriginLab Corporation). The concentrations and the inhibition rates were analyzed with Origin software using the Sigmoidal Fit methods.
| RE SULTS
| Lenvatinib inhibits the proliferation of cultured AML cells in a dose-dependent manner
In order to study the effect of lenvatinib on AML cells, we first examined whether it affected the proliferation of the target cells. We treated in vitro cultured AML Kg-1 cells with incremental concentrations of lenvatinib for 48 hours, followed by MTT assay. We then observed whether lenvatinib inhibited the proliferation of other AML cells in a dose-dependent manner as expected ( Figure 1 ; Table 1 ). Our data show that lenvatinib inhibits the proliferation of cultured AML cells in a dose-dependent manner.
| Establishing an AML subcutaneous tumor model in nude mice
To overcome the difficulty that AML cells rarely form regular solid tumors subcutaneously and to enable measurement of tumor growth, we attempted to establish a subcutaneous growth model for these hematological malignant cells. As shown in Figure 2 , injection of a cell suspensions of Kg-1 cells into subcutaneous sites in nude mice resulted in the formation of uneven and irregular shaped tumors (Figure 2A ). We next added 2% Poloxamer 407 to the Kg-1 cell suspension before subcutaneously injecting the nude mice. The size of the subcutaneous tumors became even and the shapes were homogenous ( Figure 2 ; Table 2 ). Our data show that this AML subcutaneous tumor model can be used for further evaluation of lenvatinib.
| Lenvatinib inhibits the subcutaneous growth of AML cells
The in vivo antitumor effect of lenvatinib on AML cells was then examined. In our newly established tumor models, we found that oral administration of lenvatinib inhibits the subcutaneous growth of Table 3 ). Thus, our results suggest lenvatinib can inhibit in vivo AML tumors.
| Poloxamer 407 alone does not influence the survival or growth of AML cells
To examine the effect of Poloxamer 407 on the subcutaneous growth of AML cells, we firstly established subcutaneous tumors using MHCC97-H cells, a highly aggressive HCC cell line, with/without 2% Poloxamer 407 ( Figure 4 ). We found that this concentration of Poloxamer 407 did not affect the subcutaneous growth of HCC (DNR), mitoxantrone (Mito), etoposide or 2-aminopurine-6-thiol (6-TG) have become the preferred choices for AML treatment. [15] [16] [17] Meanwhile, molecular-targeted agents, eg midostaurin or enasidenib, have been approved for AML treatment and brought new hope for AML patients. [18] [19] [20] [21] Midostaurin, developed by   Novartis Corporation, targets FLT3, c-KIT, PDGFRB, VEGFR-2 or   protein kinase C; enasidenib, developed by Agios Corporation and Celgene Corporation, targets isocitrate dehydrogenase 2 (IDH2)
to specifically inhibit the function of IDH2 mutants, reduces 2-HG levels and reverses genomic hypermethylation status of AML. [18] [19] [20] [21] However, as clinical practical experience is accumulating, these agents have not led to the hoped-for improvements in the survival of or prognosis for AML patients, suggesting that kinase inhibition There are many kinds of tumors of the blood system, and cells may form solid tumors in organs, eg lymph nodes. This makes the method used in the present work more relevant to blood tumor research.
Poloxamer 407 is a biodegradable pharmaceutical excipient that is safe to use on its own. 12 Results showed that Poloxamer 407 alone did not affect the subcutaneous growth of cells in nude mice.
The growth of tumor cells in tumor tissues is affected by the microenvironment. Therefore, it would be valuable to 
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